Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein

Core Viewpoint - A securities class action lawsuit has been filed against PepGen Inc. for allegedly making false and misleading statements regarding its lead product candidate, PGN-EDO51, and its clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit covers all investors who purchased PepGen securities between March 7, 2024, and March 3, 2025 [1]. - Investors are encouraged to contact the law firm before the lead plaintiff motion deadline of August 8, 2025 [2]. Group 2: Allegations Against PepGen - The complaint alleges that PepGen misrepresented the efficacy and safety of PGN-EDO51, claiming it was less effective than publicly stated [8]. - The CONNECT2 study was described as dangerous or deficient for obtaining FDA approval, undermining the drug's clinical, regulatory, and commercial prospects [8]. - The truth about the drug's performance began to emerge on July 30, 2024, when PepGen reported "positive clinical data" that fell short of expectations, leading to a significant stock price drop of 32.69% [3][4].